Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference

Statistically significant 133% faster time to COVID-19 clinical symptoms recovery versus standard of care (SOC)/best supportive care. Statistically significant...

Related Keywords

Georgia ,United States ,Australia ,California ,Taiwan ,San Diego ,Canada ,Taiwanese ,Senhwa Biosciences ,Senhwa Bioscience ,Chris Recknor ,Senhwa Biosciences Inc ,Us National Institute Of Health ,Human Services ,Biomedical Advanced Research ,Us Department Of Health ,Development Authority ,Advanced Research ,Casein Kinase ,Best Supportive Care ,Emergency Use ,Further Study ,Orphan Drug Designation ,Rare Pediatric Disease Drug Designation ,Nc ,